Skip to main content
Erschienen in: Clinical and Experimental Nephrology 5/2017

03.03.2017 | Review article

Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy

verfasst von: Hiroshi Tanaka, Kensuke Joh, Tadaatsu Imaizumi

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which occurs frequently in the early stages of pediatric-onset cases. Since SLE is a chronic disease associated with frequent disease flares and effective and safe maintenance therapy is required for achieving a favorable outcome, optimal treatment for LN in pubertal patients is a great challenge that remains to be overcome. Although its etiology remains unclear, it has been reported that the innate and adaptive immune systems have been reported to play an important role in the pathogenesis of SLE. However, studies of drugs that have been useful in controlling inflammatory pathways mediated by the innate and adaptive immune systems are now underway. In clinical practice, recent advances in the management of LN, together with earlier renal biopsy and selective use of aggressive immunosuppressive therapy, have contributed to a favorable outcome in children and adolescents with LN. However, the balance of the efficacy of treatment in terms of long-term prognosis and its adverse effects should be weighed in determining the treatment strategy.
Literatur
4.
Zurück zum Zitat Lee PY, Yeh KW, Yao TC, Lee WI, Lin YJ, Huang JL. The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus: a 20-year experience in Asia. Lupus. 2013;22:1534–40.CrossRefPubMed Lee PY, Yeh KW, Yao TC, Lee WI, Lin YJ, Huang JL. The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus: a 20-year experience in Asia. Lupus. 2013;22:1534–40.CrossRefPubMed
5.
Zurück zum Zitat Kawasaki Y, Ohara S, Miiazaki K, Kanno S, Ono A, Suyama K, Sato M, Suzuki S, Maeda R, Nagasawa K, Hosoya M. Incidence and prognosis of systemic lupus erythematosus in a 35 years period in Fukushima, Japan. Pediatr Int. 2015;57:650–5.CrossRefPubMed Kawasaki Y, Ohara S, Miiazaki K, Kanno S, Ono A, Suyama K, Sato M, Suzuki S, Maeda R, Nagasawa K, Hosoya M. Incidence and prognosis of systemic lupus erythematosus in a 35 years period in Fukushima, Japan. Pediatr Int. 2015;57:650–5.CrossRefPubMed
6.
Zurück zum Zitat Kawasaki Y. The pathogenesis and treatment of lupus nephritis. J Clin Pediatr Rheumatol (Tokyo). 2015;6:3–10 (Japanese). Kawasaki Y. The pathogenesis and treatment of lupus nephritis. J Clin Pediatr Rheumatol (Tokyo). 2015;6:3–10 (Japanese).
7.
Zurück zum Zitat Takei S, Maeno N, Shigemori M, Imanaka H, Mori H, Nerome Y, Kanekura S, Takezaki T, Hokonohara M, Miyata K, Fujikawa S. Clinical features of Japanese children and adolescents with systemic lupus erythematosus: results of 1980–1994 survey. Acta Paediatr Jpn. 1997;39:250–6.CrossRefPubMed Takei S, Maeno N, Shigemori M, Imanaka H, Mori H, Nerome Y, Kanekura S, Takezaki T, Hokonohara M, Miyata K, Fujikawa S. Clinical features of Japanese children and adolescents with systemic lupus erythematosus: results of 1980–1994 survey. Acta Paediatr Jpn. 1997;39:250–6.CrossRefPubMed
8.
Zurück zum Zitat Bertsias G, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adults and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.CrossRefPubMedPubMedCentral Bertsias G, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adults and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.CrossRefPubMedPubMedCentral
9.
10.
Zurück zum Zitat Vachvanichsanong P, McNel E. Pediatric lupus nephritis: more options, more chances? Lupus. 2013;22:545–53.CrossRefPubMed Vachvanichsanong P, McNel E. Pediatric lupus nephritis: more options, more chances? Lupus. 2013;22:545–53.CrossRefPubMed
11.
Zurück zum Zitat Sato VA, Marques ID, Goldenstein PT, et al. Lupus nephritis is more severe in children and adolescents than older adults. Lupus. 2012;21:978–83.CrossRefPubMed Sato VA, Marques ID, Goldenstein PT, et al. Lupus nephritis is more severe in children and adolescents than older adults. Lupus. 2012;21:978–83.CrossRefPubMed
12.
Zurück zum Zitat Tanaka H, Tateyama T, Waga S. Methylprednisolone pulse therapy in Japanese children with severe lupus nephritis. Pediatr Nephrol. 2001;16:817–9.CrossRefPubMed Tanaka H, Tateyama T, Waga S. Methylprednisolone pulse therapy in Japanese children with severe lupus nephritis. Pediatr Nephrol. 2001;16:817–9.CrossRefPubMed
13.
Zurück zum Zitat Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton). 2014;19:11–20.CrossRef Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton). 2014;19:11–20.CrossRef
14.
Zurück zum Zitat Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2015;18:182–91.CrossRefPubMed Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2015;18:182–91.CrossRefPubMed
15.
Zurück zum Zitat Ikeda F, Aizawa-Yashiro T, Watanabe S, Tsuruga K, Tanaka H. Single dose of rituximab for pediatric-onset refractory systemic lupus erythematosus. Lupus. 2013;22:1541–3.CrossRefPubMed Ikeda F, Aizawa-Yashiro T, Watanabe S, Tsuruga K, Tanaka H. Single dose of rituximab for pediatric-onset refractory systemic lupus erythematosus. Lupus. 2013;22:1541–3.CrossRefPubMed
16.
Zurück zum Zitat Brader-Meunier B, Amengaud JB, Haddad E, Salomon R, Deschênes G, Koné-Paut I, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005;146:648–53.CrossRef Brader-Meunier B, Amengaud JB, Haddad E, Salomon R, Deschênes G, Koné-Paut I, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005;146:648–53.CrossRef
17.
Zurück zum Zitat Berman H, Rodríguez-Pintó I, Cervera R, Gregory S, de Meis E, Rodrigues CE, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G, Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev. 2014; 13: 157–62.CrossRefPubMed Berman H, Rodríguez-Pintó I, Cervera R, Gregory S, de Meis E, Rodrigues CE, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G, Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev. 2014; 13: 157–62.CrossRefPubMed
18.
Zurück zum Zitat Watanabe N. A summarization of the clinical studies for children with systemic lupus erythematosus by the Japanese Ministry of Health and Welfare study group: an annual report in 1985. In A study for diagnosis and treatment in children with collagen diseases in Japan. Ueta Y, Eds. P. 9–14, Tokyo, 1985. Watanabe N. A summarization of the clinical studies for children with systemic lupus erythematosus by the Japanese Ministry of Health and Welfare study group: an annual report in 1985. In A study for diagnosis and treatment in children with collagen diseases in Japan. Ueta Y, Eds. P. 9–14, Tokyo, 1985.
19.
Zurück zum Zitat Wenderfer SE, Lane JC, Shatat IF, von Scheven E, Ruth NM. Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest pediatric nephrology consortium and the childhood arthritis and rheumatology research alliance. Pediatr Rheumatol. 2015;13:26. (doi:10.1186/s12969-015-0024-x).CrossRef Wenderfer SE, Lane JC, Shatat IF, von Scheven E, Ruth NM. Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest pediatric nephrology consortium and the childhood arthritis and rheumatology research alliance. Pediatr Rheumatol. 2015;13:26. (doi:10.​1186/​s12969-015-0024-x).CrossRef
20.
Zurück zum Zitat Sinha R, Raut S. Pediatric lupus nephritis: management update. World. J Nephrol. 2014;3:16–23. Sinha R, Raut S. Pediatric lupus nephritis: management update. World. J Nephrol. 2014;3:16–23.
21.
Zurück zum Zitat Tanaka H, Watanabe S, Aizawa-Yashiro T, Oki E, Kumagai N, Tsuruga K, Ito E. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract. 2012;121:c165–73.PubMed Tanaka H, Watanabe S, Aizawa-Yashiro T, Oki E, Kumagai N, Tsuruga K, Ito E. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract. 2012;121:c165–73.PubMed
22.
Zurück zum Zitat Tanaka H, Tsuruga K, Watanabe S, Aizawa-Yashiro T, Imaizumi T. Treatment of young patients with lupus nephritis using calcineurin inhibitors. World. J Nephrol. 2012;1:177–83.CrossRefPubMedPubMedCentral Tanaka H, Tsuruga K, Watanabe S, Aizawa-Yashiro T, Imaizumi T. Treatment of young patients with lupus nephritis using calcineurin inhibitors. World. J Nephrol. 2012;1:177–83.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr. 2000;136:243–7.CrossRefPubMed Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr. 2000;136:243–7.CrossRefPubMed
24.
Zurück zum Zitat Vachvanichsanong P, Dissaneewate P, McNeil E. Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis. Int Urol Nephrol. 2013;45:1301–8.CrossRefPubMed Vachvanichsanong P, Dissaneewate P, McNeil E. Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis. Int Urol Nephrol. 2013;45:1301–8.CrossRefPubMed
25.
Zurück zum Zitat Fujinaga S, Kaneko K, Ohtomo Y, Murakami H, Takada M, Akashi S, Hira M, Yamashiro Y. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol. 2005;20:1500–3.CrossRefPubMed Fujinaga S, Kaneko K, Ohtomo Y, Murakami H, Takada M, Akashi S, Hira M, Yamashiro Y. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol. 2005;20:1500–3.CrossRefPubMed
26.
Zurück zum Zitat Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, Kondo Y, Suzuki J. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract. 2008;110:c73–9.CrossRefPubMed Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, Kondo Y, Suzuki J. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract. 2008;110:c73–9.CrossRefPubMed
27.
Zurück zum Zitat Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E. Mizoribine intermittent pulse therapy for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol. 2008;27:85–9.CrossRefPubMed Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E. Mizoribine intermittent pulse therapy for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol. 2008;27:85–9.CrossRefPubMed
28.
Zurück zum Zitat Kuramoto T, Daikoku T, Yoshida Y, Takemoto M, Oshima K, Eizuru Y, Kanda Y, Miyawaki T, Shiraki K. Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J Pharmacol Exp Ther. 2010;333:816–21.CrossRefPubMed Kuramoto T, Daikoku T, Yoshida Y, Takemoto M, Oshima K, Eizuru Y, Kanda Y, Miyawaki T, Shiraki K. Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J Pharmacol Exp Ther. 2010;333:816–21.CrossRefPubMed
29.
Zurück zum Zitat Kizawa T, Nozawa T, Kikuchi M, Nagahama K, Okudela K, Miyamae T, Imagawa T, Nakamura T, Mori M, Yokota S, Tsutsumi H. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Mod Rheumatol. 2015;25:210–4.CrossRefPubMed Kizawa T, Nozawa T, Kikuchi M, Nagahama K, Okudela K, Miyamae T, Imagawa T, Nakamura T, Mori M, Yokota S, Tsutsumi H. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Mod Rheumatol. 2015;25:210–4.CrossRefPubMed
30.
Zurück zum Zitat Kittanamongkolchai W, Rukrung C, Supasiri T, Lertjirachai I, Somparn P, Chariyavilaskul P, Avihingsanon Y. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Lupus. 2013;22:727–32.CrossRefPubMed Kittanamongkolchai W, Rukrung C, Supasiri T, Lertjirachai I, Somparn P, Chariyavilaskul P, Avihingsanon Y. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Lupus. 2013;22:727–32.CrossRefPubMed
31.
Zurück zum Zitat Tsujimura S, Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol. 2012;16:102–8.CrossRefPubMed Tsujimura S, Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol. 2012;16:102–8.CrossRefPubMed
32.
Zurück zum Zitat Mok CC. Pro: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant. 2016;31:1561–6.CrossRefPubMed Mok CC. Pro: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant. 2016;31:1561–6.CrossRefPubMed
33.
Zurück zum Zitat Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001–10.CrossRefPubMedPubMedCentral Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001–10.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Aragon E, Resontoc LP, Chan YH, Lau YW, Tan PH, Loh HL, Ng KH, Yap HK. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus. 2016;25:399–406.CrossRefPubMed Aragon E, Resontoc LP, Chan YH, Lau YW, Tan PH, Loh HL, Ng KH, Yap HK. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus. 2016;25:399–406.CrossRefPubMed
35.
Zurück zum Zitat Tanaka H, Aizawa T, Watanabe S, Oki E, Tsuruga K, Imaizumi T. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus. 2014;23:813–8.CrossRefPubMed Tanaka H, Aizawa T, Watanabe S, Oki E, Tsuruga K, Imaizumi T. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus. 2014;23:813–8.CrossRefPubMed
36.
Zurück zum Zitat Evans R, Salama AD. Update on rituximab: an established treatment for all immune-mediated kidney diseases? Nephron Clin Pract. 2014;126:97–109.CrossRefPubMed Evans R, Salama AD. Update on rituximab: an established treatment for all immune-mediated kidney diseases? Nephron Clin Pract. 2014;126:97–109.CrossRefPubMed
37.
Zurück zum Zitat Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23:413–9.CrossRefPubMed Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23:413–9.CrossRefPubMed
38.
Zurück zum Zitat Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, Moorthy N. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol. 2014;12:3. doi:10.1186/1546-0096-12-3.CrossRef Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, Moorthy N. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol. 2014;12:3. doi:10.​1186/​1546-0096-12-3.CrossRef
39.
Zurück zum Zitat Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, Kaneko Y, Maeshima A, Kuroiwa T, Nojima Y. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24:618–25.CrossRefPubMed Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, Kaneko Y, Maeshima A, Kuroiwa T, Nojima Y. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24:618–25.CrossRefPubMed
40.
Zurück zum Zitat Tanaka H, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito Y, Sato N, Kawasaki Y, Suzuki J. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis. Clin Rheumatol. 2010;29:1049–54.CrossRefPubMed Tanaka H, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito Y, Sato N, Kawasaki Y, Suzuki J. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis. Clin Rheumatol. 2010;29:1049–54.CrossRefPubMed
41.
Zurück zum Zitat Aizawa T, Imaizumi T, Tsuruga K, Watanabe S, Chiba Y, Matsumiya T, Yoshida H, Tanaka H. Mizoribine selectively attenuates monocyte chemoattractant protein-1 production in cultured human glomerular mesangial cell: a possible benefit of its use in the treatment of lupus nephritis. Nephrology (Carlton). 2014;19:47–52.CrossRef Aizawa T, Imaizumi T, Tsuruga K, Watanabe S, Chiba Y, Matsumiya T, Yoshida H, Tanaka H. Mizoribine selectively attenuates monocyte chemoattractant protein-1 production in cultured human glomerular mesangial cell: a possible benefit of its use in the treatment of lupus nephritis. Nephrology (Carlton). 2014;19:47–52.CrossRef
42.
Zurück zum Zitat Tanaka H, Tsuruga K, Imaizumi T. Mizoribine in the treatment of pediatric-onset glomerular disease: revisit its beneficial effects from the histological standpoint. World J Pediatr. 2015;11:108–12.CrossRefPubMed Tanaka H, Tsuruga K, Imaizumi T. Mizoribine in the treatment of pediatric-onset glomerular disease: revisit its beneficial effects from the histological standpoint. World J Pediatr. 2015;11:108–12.CrossRefPubMed
43.
Zurück zum Zitat Hara S, Umino D, Someya T, Fujinaga S, Ohtomo Y, Murakami H, Shimizu T. Protective effects of mizoribine on cyclosporine A nephropathy in rats. Pediatr Res. 2009;66:524–7.CrossRefPubMed Hara S, Umino D, Someya T, Fujinaga S, Ohtomo Y, Murakami H, Shimizu T. Protective effects of mizoribine on cyclosporine A nephropathy in rats. Pediatr Res. 2009;66:524–7.CrossRefPubMed
44.
Zurück zum Zitat Anders HS. Pseudoviral immunity: a novel concept for lupus. Trend Mol Med 2009;15:553–61.CrossRef Anders HS. Pseudoviral immunity: a novel concept for lupus. Trend Mol Med 2009;15:553–61.CrossRef
46.
Zurück zum Zitat Hagberg N, Rönnblom L. Systemic lupus erythematosus: a disease with a dysregulated type I interferon system. Scand J Immunol. 2015;82:199–207.CrossRefPubMed Hagberg N, Rönnblom L. Systemic lupus erythematosus: a disease with a dysregulated type I interferon system. Scand J Immunol. 2015;82:199–207.CrossRefPubMed
47.
Zurück zum Zitat Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–94.CrossRefPubMed Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–94.CrossRefPubMed
48.
Zurück zum Zitat Watanabe S, Imaizumi T, Tsuruga K, Aizawa T, Ito T, Matsumiya T, Yoshida H, Joh K, Ito E, Tanaka H. Glomerular expression of myxovirus resistance protein 1 (Mx1) in human mesangial cells: possible activation of innate immunity in the pathogenesis of lupus nephritis. Nephrology (Carlton). 2013;18:833–7.CrossRef Watanabe S, Imaizumi T, Tsuruga K, Aizawa T, Ito T, Matsumiya T, Yoshida H, Joh K, Ito E, Tanaka H. Glomerular expression of myxovirus resistance protein 1 (Mx1) in human mesangial cells: possible activation of innate immunity in the pathogenesis of lupus nephritis. Nephrology (Carlton). 2013;18:833–7.CrossRef
49.
Zurück zum Zitat Imaizumi T, Aizawa T, Segawa C, Shimada M, Tsuruga K, Kawaguchi S, Matsumiya T, Yoshida H, Joh K, Tanaka H. Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1, in human mesangial cells. Clin Exp Nephrol. 2015;19:761–70.CrossRefPubMed Imaizumi T, Aizawa T, Segawa C, Shimada M, Tsuruga K, Kawaguchi S, Matsumiya T, Yoshida H, Joh K, Tanaka H. Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1, in human mesangial cells. Clin Exp Nephrol. 2015;19:761–70.CrossRefPubMed
50.
Zurück zum Zitat Imaizumi T, Shimada T, Matsumiya T, Yoshida H, Watanabe S, Tsuruga K, Kawaguchi S, Murakami K, Joh K, Tanaka H. Interferon-stimulated gene 15, a type I interferon-dependent transcript, is involved in a negative feedback loop in innate immune reactions in human mesangial cells. Nephron. 2016;132:144–52.CrossRefPubMed Imaizumi T, Shimada T, Matsumiya T, Yoshida H, Watanabe S, Tsuruga K, Kawaguchi S, Murakami K, Joh K, Tanaka H. Interferon-stimulated gene 15, a type I interferon-dependent transcript, is involved in a negative feedback loop in innate immune reactions in human mesangial cells. Nephron. 2016;132:144–52.CrossRefPubMed
51.
Zurück zum Zitat Imaizumi T, Hayakari R, Matsumiya T, Yoshida H, Tsuruga K, Watanabe S, Kawaguchi S, Tanaka H (2017) Chloroquine attenuates TLR3/IFNÎ2 signaling in cultured normal human mesangial cells: a possible protective effect against renal damage in lupus nephritis. Mod Rheumatol 1–6 Imaizumi T, Hayakari R, Matsumiya T, Yoshida H, Tsuruga K, Watanabe S, Kawaguchi S, Tanaka H (2017) Chloroquine attenuates TLR3/IFNÎ2 signaling in cultured normal human mesangial cells: a possible protective effect against renal damage in lupus nephritis. Mod Rheumatol 1–6
Metadaten
Titel
Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy
verfasst von
Hiroshi Tanaka
Kensuke Joh
Tadaatsu Imaizumi
Publikationsdatum
03.03.2017
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 5/2017
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1381-1

Weitere Artikel der Ausgabe 5/2017

Clinical and Experimental Nephrology 5/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.